Sep 2026· Advancement of science· 0 citations· 57 references
Medicine
TL;DR
MolDBG achieves competitive performance across all three tasks while enabling site‐specific affinity prediction and interpretable binding‐site discovery, and generalizes to structurally elusive targets, including cryptic pockets and intrinsically disordered proteins.
Abstract
ABSTRACT Unifying drug‐target affinity prediction and targeted molecular design within a single interpretable framework remains challenging. Many sequence‐based affinity and design methods rely on global target representations without explicitly modeling binding regions, leading to site‐level ambiguity in both screening and design. By contrast, structure‐based methods require high‐quality structural data and are poorly suited to dynamic targets. In this study, a new model named MolDBG is proposed as a unified site‐aware framework that combines affinity prediction, binding‐site identification, and affinity‐conditioned molecular generation within a single architecture. With binding‐site supervision, MolDBG prioritizes interaction‐critical residues before learning drug‐target representations, reducing false positives from misaligned binding sites and improving interpretability. MolDBG achieves competitive performance across all three tasks while enabling site‐specific affinity prediction and interpretable binding‐site discovery. The framework generalizes to structurally elusive targets, including cryptic pockets and intrinsically disordered proteins. Overall, these results demonstrate that MolDBG is a promising framework for molecular design and screening.
This work proposes MF‐Net, a unified hierarchical multiscale fusion framework that integrates sequence‐, atomic‐, and fragment‐level representations to model drug–target interactions across complementary scales and demonstrates strong early enrichment across multiple virtual screening datasets.
Shuo Liu, Xiang Zhang, Hai-Xia Feng et al.· Advancement of science· 0 citations
Accurate identification of protein−nucleic acid binding sites is essential for elucidating molecular mechanisms and for enabling structure-based drug discovery. Existing computational approaches struggle to jointly model sequence, structure, and domain knowledge, which limits both predictive accuracy and interpretabi...
Wen-Yu Xi, Ru-Heng Wang, Xiu-Cai Ye et al.· ACS Synthetic Biology· 0 citations
Unraveling the precise mechanisms of protein-ligand recognition remains a cornerstone of structure-based drug discovery. While recent deep learning advances have accelerated computational screening, a critical bottleneck persists: binding pocket characterization is often rigidly disconnected from the querying molecule'...
Yun-Feng Li, Xing-Yu Liu, Yi-Jia Liu et al.· European journal of medicina...· 0 citations
HelixDTA is introduced, a deep learning framework featuring a parallel dual-branch architecture that independently learns representations from two distinct but complementary modalities: sequence context and complete target structures that demonstrates significant potential to empower precision drug design and accelerat...
Shang Lou, Xu-Hua Li, Yu-Jie Peng et al.· Journal of Chemical Informat...· 0 citations
MIRAGE provides an interpretable and robust framework for structure-aware prediction, with potential applications in protein engineering and drug design, and explicitly modeling multi-level interactions is important for accurately capturing the determinants of binding affinity.
Molecular representation learning is central to computer-aided drug discovery. Molecular graphs, SMILES strings, and 3D conformations provide complementary structural information, yet many multimodal approaches encode these views independently and align them only at a later stage, limiting fine-grained cross-modal inte...
Lin-Qing Mo, Jia-Yu Zhou, Bin Chen· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.